ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2018 (the “Period”). Key Highlights (including post Period review) Stable financial performance over the Period – Cash balance of £4.9 million (31 December 2017: £2.7 million) – Loss for…

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company provides an update on ongoing activities. Lupuzor™  Lupuzor™ is the Company’s late stage asset for Lupus, a potential life threatening auto-immune disease. Following the conclusion of the pivotal Phase III trial in 2018, ImmuPharma continues to look at opportunities which the Board believes over…

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company provides an update in relation to its discussions with Incanthera Limited (“Incanthera”) on its Nucant cancer programme. Background On 7 September 2018, ImmuPharma announced that it had signed Heads of Terms with Incanthera, a specialist oncology company, and that it had invested £2m into…

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company today announces a corporate update. Click here to view

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company is pleased to announce that on 25 February 2019, the peer reviewed research journal ‘Nature Communications’ published a fundamental scientific publication on the proprietary technology Urelix™ from UREkA Sarl (“Ureka”), ImmuPharma’s subsidiary. Ureka, based at the IECB in Bordeaux, France, is carrying out research…

APPOINTMENT OF NOMINATED ADVISOR ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company is pleased to announce the appointment of SPARK Advisory Partners Limited (“SPARK”) as the Company’s Nominated Advisor (“NOMAD”), with immediate effect. Commenting on the appointment, ImmuPharma’s Chairman, Tim McCarthy, said: “I am delighted to announce the appointment of SPARK as…

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company is pleased to provide an update on ongoing activities. Key highlights: Lupuzor™ –  Lupuzor™ ‘Managed Access Programme’ –  Phase III ‘open label extension’ Nucant (cancer) program: Clinical development collaboration with Incanthera Limited Ureka subsidiary  Nominated Adviser status Lupuzor™ Managed Access Programme Lupuzor™ is ImmuPharma’s late…

ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, announces that the Directors are aware of the proposed merger of its current nominated adviser (“NOMAD”), Northland Capital Partners (“Northland”) with SP Angel Corporate Finance LLP. The Directors have also been informed that Northland has voluntarily agreed to relinquish its NOMAD status and will…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2018 (the “Period”). Key Highlights Lupuzor Lupuzor™ demonstrated a superior response rate over placebo (52.5% vs 44.6% “responders”) in the primary analysis on the Full Analysis Set…

ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, is pleased to announce that it has, with immediate effect, appointed Stanford Capital Partners and SI Capital as joint brokers. They will work in conjunction with Northland Capital Partners who are the Company’s NOMAD and broker. Commenting on the announcement, Tim McCarthy, Chairman of…

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company today announces a corporate update. Click here to view

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed.

Positive results of P140 (Lupuzor™ or Forigerimod) published in the Journal of Autoimmunity in a model of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) The T cell modulator P140 significantly reduced the disease in the murine preclinical model Data provides evidence for the expansion of P140 in an autoimmune indication with ‘Orphan Drug Designation’ ImmuPharma PLC (LSE:IMM),…

Notice of Annual general Meeting on 28 June 2018 @ 10.30 AM Venue: Sky Light City Tower, 50 Basinghall Street, London, EC2 ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that the Annual Report and Accounts for the year ended 31 December 2017 has been posted to shareholders.…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce further analysis of the results from its pivotal Phase III trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, a potentially life threatening auto-immune disease. This new data follows the top-line trial results published on 17 April…

Download here

ImmuPharma PLC (LON:IMM) CEO Dimitri Dimitriou and Chairman Tim McCarthy discuss with Proactive Investors the top-line results from their phase III trial of the drug Lupuzor™. The data revealed Lupuzor™ was more effective than the placebo (52.5% versus 44.6%) however because the response rate for those taking the non-active medication plus the “standard of care”…

Download here

Download here

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces the results of its pivotal Phase III trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus. Key highlights: Lupuzor™ demonstrated a superior response rate over placebo* (52.5% vs 44.6% “responders”**) in the primary analysis on the Full Analysis Set of…

ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, is pleased to announce that it has with immediate effect appointed Bryan, Garnier & Co. Limited as its joint corporate broker to act alongside Northland Capital Partners who remain the Company’s Nominated Adviser and joint corporate broker. Tim McCarthy, Chairman of Immupharma, commented: “We…